Navigate all the latest information in myeloproliferative neoplasms, arranged by experts and health care professionals. Listed below are recently added expert opinions.
Givinostat in polycythemia vera: Long-term safety and efficacy
Polycythemia vera (PV) is a BCR-ABL1-negative subtype of myeloproliferative neoplasms (MPN), characterized by excessive erythroid...
Should patients with myelofibrosis be transplanted before or after ruxolitinib failure?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MPN Hub...
What needs to be considered in patients with MPN with COVID-19?
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We...
What are the promising new agents for patients with myelofibrosis?
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked,...
What’s new for the management of polycythemia vera?
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Heinz Gisslinger, Medical University of Vienna, Vienna, AT. We asked, What’s...
When would you switch a patient with myelofibrosis from ruxolitinib?
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Haifa Kathrin Al-Ali, University Hospital Halle (Saale),...
How effective are JAK inhibitor combinations for patients with myelofibrosis?
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Srdan Verstovsek, MD Anderson Cancer Center,...
When should we give JAK inhibitors to patients with MF in the peri-transplant setting?
During the 2021 TCT Meetings Digital Experience, the MPN Hub spoke to Ruben A. Mesa, UT Health San Antonio, San...
Alessandro M. Vannucchi
Brady L. Stein
Craig W. Freyer
Haifa Kathrin Al-Ali
Jacqueline S. Garcia
Raajit K. Rampal
Ruben A. Mesa